Cursor Might Be SpaceX’s Ticket to $600 Per Share
SpaceX just dropped $60 billion on an AI coding firm, and analysts are starting to wonder if that single acquisition rewrites the entire bull case for the stock. The space story is real, but…
Investing
All Investing Articles
Newest first · Page 210
Inflation Falls for 2 Months Straight — Is a Fed September Rate Hike Still on the Table?
Wall Street spent July bracing for a hawkish September from Fed Chair Kevin Warsh, with rate-hike odds sitting above 50%. Then two back-to-back inflation reports landed, and the math fell apart faster than traders…
Michael Burry Sounds the Alarm Again: AI Is a Circular Financing Web With Nvidia In the Middle
Michael Burry is pointing at a $770 billion AI spending wave and asking whether the money circling through hyperscalers, chip makers, and AI labs is creating real value or just the appearance of it.
Are Stablecoins Making XRP Unnecessary?
Ripple closed ten major deals in 2026 and not one of them settled in XRP, which raises a question the coin's supporters have struggled to answer about what the token actually does now.
Cisco Drops 7% on Gross Margin Fears: Five Firms Raise CSCO Price Target Anyway
Cisco beat earnings, crushed revenue estimates, and racked up billions in AI orders, yet the stock cratered 7% anyway. Five analyst firms still raised their price targets, but the spread between the most bearish…
Big Beat, Big Backlog, Big Caveats: Inside Super Micro’s 33% Upside Potential
Super Micro just posted its strongest quarter in years, yet shares barely moved. Understanding why the market shrugged reveals exactly what needs to go right before the bulls can claim victory.
CoreWeave’s Spike Hasn’t Erased 3-Month Losses: Why Trusted Wall Street Pro Expects 65% Post-Spike Gains
CoreWeave's Q2 blowout sent shares surging, but the stock still sits deep in the red over three months while one Wall Street firm holds a price target that implies a runway most investors are…
Meta’s $145B Bet Has Wall Street Terrified—Here’s Why Bargain Hunters Are Buying Hand Over Fist
Mark Zuckerberg is sparring with UFC fighters and betting the house on AI infrastructure, and Wall Street still can't decide if it's genius or recklessness. What bargain hunters see in Meta right now might…
Intel’s Best Growth in 15 Years: 25% Revenue Surge and Our New Price Target
Intel just posted its strongest revenue growth in over 15 years, yet shares sit more than 30% below their recent peak after a massive stock offering rattled investors. Whether that gap is a buying…
Jim Cramer Says Skip Poet and Buy These 2 Proven Photonics Stocks for AI Data Centers in August
Jim Cramer took a hard pass on one buzzy photonics name while steering investors toward two stocks already hauling in NVIDIA investment and posting triple-digit gains. Find out which companies made his short list…
12 Things Not To Do If You Won The $1.04 Billion Lottery
Most lottery winners who end up broke made the same avoidable mistakes in the first few months after winning. Knowing what not to do turns out to matter far more than any financial strategy.
U.S. Budget Deficits Just Surged to $432.3 billion in July While Trump Weighs Brand-New Tax Cuts
Washington is floating brand-new tax cuts at the exact moment the federal deficit is blowing past levels not seen since the pandemic, and bond markets are already reacting. Here is what the latest Treasury…
Household Debt Just Fell for the First Time in 6 Years — Here’s Why That’s Bad News
American households just posted their first debt decline in six years, and economists are calling it a warning sign rather than a milestone. The real numbers buried inside the Federal Reserve's latest report paint…
Hold Intel And Strictly Follow These Binary Catalysts
Intel has staged one of the most dramatic stock revivals in recent memory, but two unresolved catalysts will either confirm the turnaround as real or expose this year's triple-digit rally as a trade that…
Inside Latigo Biotherapeutics’ IPO: A Non-Opioid Pain Bet Goes Public
A California biotech just raised $350 million promising to out-perform opioids without the addiction risk, and its auditors were still warning about survival just months ago. Here is what the science and the filings…